Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108

Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of
CL-108

CHARLESTON, S.C., May 18 /PRNewswire/ -- Charleston Laboratories, Inc., an
emerging specialty pharmaceutical company dedicated to reducing opioid-induced
nausea and vomiting (OINV) in opioid pharmaceuticals, announced today they
successfully completed the Exploratory Bioequivalence Study on CL-108,
Charleston Labs' first drug candidate. "These are promising data on our
immediate-release low-dose antiemetic," said Dr. Ray Takigiku, Chief Operating
Officer at Charleston Laboratories, "and confirm our progression in the
clinical development of CL-108."

Dr. Bernard Schachtel, Chief Scientific Officer, added, "We are pleased to be
moving CL-108 directly into a Phase III efficacy trial. We conducted this
exploratory study to examine different pharmacologic and clinical features of
CL-108. While the findings need to be demonstrated in controlled clinical
trials, the pharmacokinetic data point to the efficacy of an immediate-release
low-dose anti-emetic when combined with hydrocodone and acetaminophen for
patients with acute moderate to severe pain. We will utilize key results from
this and other studies to build our pipeline of opioid pain management
products."

"We have already been approached by biotech companies interested in licensing
this novel approach of treating acute pain while reducing opioid-induced
nausea and vomiting," Mr. Paul Bosse, Chief Executive Officer at Charleston
Laboratories, continued. "Because this is a common and burdensome medical
problem, Charleston Labs will be developing several opioid products to address
this unmet patient need."

All clinical studies for Charleston Laboratories are being overseen by SRC,
Inc., a contract research organization based in Jupiter, Florida that is
renowned for its clinical trials on patients' symptoms, such as nausea, a
targeted therapeutic endpoint for Charleston Laboratories.

About Charleston Laboratories, Inc.
Charleston Laboratories Inc, headquartered in Charleston, SC, is a privately
funded specialty pharmaceutical company developing and commercializing opioid
drugs with minimal or no opioid-induced nausea and vomiting (OINV).
Charleston Laboratories intends to enter into discovery and commercialization
alliances with partners motivated to introduce novel pain therapies that
eliminate or significantly reduce nausea and vomiting.

www.charlestonlabs.com.

SOURCE Charleston Laboratories, Inc.

Paul Bosse, CEO, Charleston Laboratories, Inc., +1-843-577-2626,
pbosse@charlestonlabs.com